Nexstim Plc: Change in the Composition of the Shareholders’ Nomination Committee

Company Announcement, Helsinki, 28 September at 9 AM (EEST)


Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") is announcing a change in the composition of the Shareholders’ Nomination Committee.

Tero Weckroth representing Wetrock Capital & Consulting Oy has been appointed as a new member of the Nomination Committee. Tero Weckroth is also a member of Nexstim’s Board of Directors.

Leena Niemistö, Chairperson of the Board of Nexstim and representative of its largest shareholder, continues to chair the Nomination Committee, and Ossi Haapaniemi and Kyösti Kakkonen continue as members of the Committee.

According to the document establishing Nexstim’s Nomination Committee, it must have three to four members. The three largest shareholders of the Company each nominate one member; if a shareholder does not exercise the right to nominate a representative, the right is passed on to the next largest shareholder.

The new Nomination Committee will start its work during October.


Further information is available on the website, or by contacting:

Leena Niemistö, Chair of Board of Directors
+358 9 2727 170

The Company’s Certified Advisor is Erik Penser Bank. 

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit